Looking forward to BIO Europe in Vienna next week! Our focus will be the future of high-quality weight loss.
The success of incretins has created a critical unmet need for a solution to the muscle loss and subsequent weight regain that follows. We have developed a Phase II ready, oral therapy designed to solve this. Our approach, built on a validated GPCR platform, is to deliver a foundational muscle-preserving treatment that can be used as a standalone or as a crucial add-on to current appetite suppressants.
We are keen to connect with investors and potential partners who share our vision for defining the next generation of metabolic therapeutics. Message us to schedule a meeting!
